Kiniksa price target raised to $54 from $45 at Jefferies

Jefferies raised the firm’s price target on Kiniksa (KNSA) to $54 from $45 and keeps a Buy rating on the shares after what the firm points out was “another ‘beat & raise'” report following a “greatly positive” Q1. The firm sees strong commercial execution, continued growth on all launch metrics, and meaningful upside from further deepening the penetration into the target population as well as potential expansion into a larger population of patients, the analyst tells investors.